The recommended dosing for LEXIVA is:
-- Therapy naive adults
-- LEXIVA 1400mg twice daily
-- LEXIVA 1400mg once daily plus ritonavir 100mg once daily
-- LEXIVA 1400mg once daily plus ritonavir 200mg once daily
-- LEXIVA 700mg twice daily plus ritonavir 100mg twice daily
-- Protease inhibitor experienced adults
-- LEXIVA 700mg twice daily plus 100mg ritonavir twice daily
LEXIVA was initially approved by the FDA for use in the US in 2003. It is the first PI to offer flexible dosing options (for PI-nave patients) with no food or water restrictions.
Important Safety Information about LEXIVA
HIV medicines do not cure HIV infection/AIDS or prevent passing HIV to others.
Patients should not take LEXIVA if they have had an allergic reaction
to LEXIVA or AGENERASE(R) (amprenavir). High blood sugar, diabetes or
worsening of diabetes, and bleeding in hemophiliacs have occurred in some
patients taking protease inhibitors. When patients start taking HIV
medicines, their immune system may get stronger and could begin to fight
infections that have been hidden in their body, such as pneumonia, herpes
virus, or tuberculosis. If patients have new symptoms after starting their
HIV medicines, they should tell their doctor. Changes in body fat may occur
in some patients taking antiretroviral therapy. The cause and long-term
health effects of these conditions are not known at this time. Skin rashes
Copyright©2007 PR Newswire.
All rights reserved